UNITY Biotechnology announced the appointment of Lynne Sullivan to the permanent role of chief financial officer, effective September 1, 2020. Lynne Sullivan brings more than 20 years of experience working in the pharma and biotech industry. Sullivan worked at Biogen for over 10 years, serving as senior vice president of finance with global responsibility for corporate finance, financial planning and analysis and corporate tax. Sullivan is a member of the board of directors of four publicly traded biopharmaceutical companies, Inozyme Pharma, Solid Biosciences, resTORbio and BiomX, and most recently served as the chief financial officer for Compass Therapeutics.